FDA updates certain COVID-19 monoclonal antibody authorizations
The Food and Drug Administration Friday updated its emergency use authorizations for two intravenous infusion therapies for outpatients at risk for progressing to severe COVID-19 disease. Specifically, it updated the patient selection criteria and safety summary for the monoclonal antibodies bamlanivimab and etesevimab administered together, and the patient selection criteria for the monoclonal antibodies casirivimab with imdevimab (REGEN-CON) administered together. For details on the changes, see the FDA fact sheets for and .
Related News Articles
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…